Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanofibril adhesive with plant-based nanohydrogel for second-degree burn treatment
IRCT20250430065544N1Phase 3Recruiting
- Sponsor
- Lorestan University of Medical Sciences
- Start
- Jul 2025
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gentamicin in burn injury (2 arms), sponsored by Lorestan University of Medical Sciences. Primary endpoints: Second-degree burn wound healing, Reduction of burn pain and 5 more. Started Jul 2025; status: recruiting.
02
Drugs
gentamicin
03
Conditions
burn injury
Beyond the preview
Go deeper on IRCT20250430065544N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250430065544N1.